Roth Capital initiated coverage on SANUWAVE Health with a new price target
$SNWV
Medical/Dental Instruments
Health Care
Roth Capital initiated coverage of SANUWAVE Health with a rating of Buy and set a new price target of $49.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/3/2025 | $55.00 | Outperform | Northland Capital |
| 7/29/2025 | $49.00 | Buy | Roth Capital |
4/A - SANUWAVE Health, Inc. (0001417663) (Issuer)
4 - SANUWAVE Health, Inc. (0001417663) (Issuer)
4 - SANUWAVE Health, Inc. (0001417663) (Issuer)
EDEN PRAIRIE, Minn., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave") (NASDAQ:SNWV), a leading provider of FDA-approved next-generation wound care products, is pleased to announce that it will be attending the upcoming 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA from January 12th to January 15th 2026. Those wishing to meet with company management during the conference should reach out to [email protected] to schedule a time. About SanuwaveSanuwave Health is focused on the research, development, and commercialization of its patented, non-invasive directed energy medical systems for the repair and regeneration of skin, muscul
Healogics Wound Care Supply adds UltraMIST to its Group Purchasing Organization Healogics iSupply and Sanuwave collaborate to provide UltraMIST as an option for GPO members EDEN PRAIRIE, Minn., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave") (NASDAQ:SNWV), a leading provider of next-generation FDA-approved wound care products, is pleased to announce the addition of its UltraMIST product line to Healogics iSupply. With this expansion, UltraMIST becomes an option for iSupply members, including Wound Care Centers®, home health agencies, and skilled nursing facilities. Sanuwave plans to roll out the UltraMIST system to Healogics iSupply members at initi
Q3 2025 revenues were $11.5 million, up 22% from $9.4 million in Q3 2024. This represents the highest quarterly revenues in Company history. Q3 2025 gross margin was 77.9%, versus 75.5% in Q3 2024. GAAP Operating Income was $1.5 million for Q3 2025 versus $2.0 million in Q3 2024. Q3 2025 included stock-based compensation costs of $1.4 million versus $0 in Q3 2024. Company provides guidance for revenues of $13-$14 million for Q4 2025. EDEN PRAIRIE, Minn., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave") (NASDAQ:SNWV), a leading provider of next-generation FDA-approved wound care products, is pleased to provide its financial results for the three mo
4 - SANUWAVE Health, Inc. (0001417663) (Issuer)
4 - SANUWAVE Health, Inc. (0001417663) (Issuer)
Northland Capital initiated coverage of SANUWAVE Health with a rating of Outperform and set a new price target of $55.00
Roth Capital initiated coverage of SANUWAVE Health with a rating of Buy and set a new price target of $49.00
SCHEDULE 13D/A - SANUWAVE Health, Inc. (0001417663) (Subject)
8-K - SANUWAVE Health, Inc. (0001417663) (Filer)
10-Q - SANUWAVE Health, Inc. (0001417663) (Filer)
Q3 2025 revenues were $11.5 million, up 22% from $9.4 million in Q3 2024. This represents the highest quarterly revenues in Company history. Q3 2025 gross margin was 77.9%, versus 75.5% in Q3 2024. GAAP Operating Income was $1.5 million for Q3 2025 versus $2.0 million in Q3 2024. Q3 2025 included stock-based compensation costs of $1.4 million versus $0 in Q3 2024. Company provides guidance for revenues of $13-$14 million for Q4 2025. EDEN PRAIRIE, Minn., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave") (NASDAQ:SNWV), a leading provider of next-generation FDA-approved wound care products, is pleased to provide its financial results for the three mo
EDEN PRAIRIE, Minn., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave") (NASDAQ:SNWV), a leading provider of next-generation FDA-approved wound care products, will host a live conference call on Friday, November 7, 2025, at 8:30 AM (ET) to present its Q3 2025 financial results. Telephone access to the call will be available by dialing the following numbers: Participant Dial-in Information Toll Free: 1-800-274-8461 Toll/International: 1-203-518-9814 Conference ID: SANUWAVE OR click the link for instant telephone access to the event:https://viavid.webcasts.com/starthere.jsp?ei=1741017&tp_key=73ef3b515aMaterials for the conference call will be include
Sanuwave announces preliminary revenues of $11.4 million to $11.6 million for the third quarter ended September 30, 2025. This represents the highest quarterly revenues in Company history. Q3 2025 revenue increased between 22% and 24% vs Q3 2024 and between 12% and 14% sequentially vs the prior quarter First nine months of 2025 revenue increased 39-40% vs first nine months of 2024. EDEN PRAIRIE, Minn., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave") (NASDAQ:SNWV), a leading provider of next-generation FDA-approved wound care products, today announced that revenues for the third quarter of 2025 are expected to be in the range of $11.4 to $11.6 millio
EDEN PRAIRIE, Minn., June 03, 2025 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave") (NASDAQ:SNWV), a leading provider of next-generation FDA-approved wound care products, is pleased to announce the hiring of Dustin Libby as its EVP of commercial operations. Libby brings 20 years of medical device experience focused on commercial growth, sales operations, and launch execution. His career includes leadership roles at Abiomed where, as director of commercial operations, he helped scale a $15M surgical business to over $500M in revenue. Other roles include experience at Smith & Nephew, Arthrex, and Hill-ROM, where he directed sales enablement, operational strat
EDEN PRAIRIE, Minn., May 28, 2025 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave") (NASDAQ:SNWV), a leading provider of next-generation FDA-approved wound care products, is pleased to announce the addition of Greg Bazar to its Board of Directors. Bazar brings decades of leadership experience in engineering, technology, and cybersecurity to Sanuwave's Board of Directors. He currently serves as Chairman of the Board at Simpatico Systems, a company he founded to deliver advanced IT and cybersecurity solutions. Previously, he was the first employee at intelligent connectivity provider 3D-P, where he played a pivotal role in the company's growth and strategic direction,